BRIEF REPORT - COMPLETE DEFICIENCY OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 DUE TO A FRAME-SHIFT MUTATION

被引：222
作者：
FAY, WP
SHAPIRO, AD
SHIH, JL
SCHLEEF, RR
GINSBURG, D
机构：
[1] UNIV MICHIGAN, MED CTR,SCH MED,DEPT INTERNAL MED,4520 MSRB 1, 1150 W MED CTR DR, ANN ARBOR, MI 48109 USA
[2] ANN ARBOR VET AFFAIRS HOSP, DIV CARDIOL, ANN ARBOR, MI USA
[3] ANN ARBOR VET AFFAIRS HOSP, RES SERV, ANN ARBOR, MI USA
[4] INDIANA UNIV, MED CTR, INDIANAPOLIS, IN 46204 USA
[5] SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA USA
[6] UNIV MICHIGAN, SCH MED, DEPT HUMAN GENET, ANN ARBOR, MI 48104 USA
[7] UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48104 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 1992年 / 327卷 / 24期
关键词：
D O I：
10.1056/NEJM199212103272406
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THE process of plasminogen activation is considered a critical component of diverse biologic systems in humans. This reaction, which is catalyzed in vivo by tissue-type and urokinase-type plasminogen activators, results in the conversion of plasminogen to plasmin. Plasmin has an essential role in maintaining vascular patency by converting fibrin to soluble fibrin-degradation products. In addition, plasminogen activators have been implicated in the regulation of embryogenesis, angiogenesis, ovulation, inflammation, and tumor metastasis,1 suggesting that the plasminogen-activation system is an important mediator of tissue remodeling and cell migration. The activity of plasminogen activators is precisely regulated by several mechanisms.1 Critical among these… © 1992, Massachusetts Medical Society. All rights reserved.
引用
收藏
页码：1729 / 1733
页数：5
相关论文
共 28 条
  • [1] BOSMA PJ, 1988, J BIOL CHEM, V263, P9129
  • [2] BRODBECK RM, 1992, J BIOL CHEM, V267, P294
  • [3] ALTERING THE GENOME BY HOMOLOGOUS RECOMBINATION
    CAPECCHI, MR
    [J]. SCIENCE, 1989, 244 (4910) : 1288 - 1292
  • [4] CARRELL RW, 1989, MOL BIOL MED, V6, P35
  • [5] FREQUENT MUTATIONS IN THE P53 TUMOR SUPPRESSOR GENE IN HUMAN LEUKEMIA T-CELL LINES
    CHENG, J
    HAAS, M
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (10) : 5502 - 5509
  • [6] THE MOLECULAR DEFECT IN TYPE-IIB VONWILLEBRAND DISEASE - IDENTIFICATION OF 4 POTENTIAL MISSENSE MUTATIONS WITHIN THE PUTATIVE GPLB BINDING DOMAIN
    COONEY, KA
    NICHOLS, WC
    BRUCK, ME
    BAHOU, WF
    SHAPIRO, AD
    BOWIE, EJW
    GRALNICK, HR
    GINSBURG, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 87 (04) : 1227 - 1233
  • [7] GENETIC-VARIATION AT THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 LOCUS IS ASSOCIATED WITH ALTERED LEVELS OF PLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY
    DAWSON, S
    HAMSTEN, A
    WIMAN, B
    HENNEY, A
    HUMPHRIES, S
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01): : 183 - 190
  • [8] DIEVAL J, 1991, BLOOD, V77, P528
  • [9] THE PRIMARY PLASMINOGEN-ACTIVATOR INHIBITORS IN ENDOTHELIAL-CELLS, PLATELETS, SERUM, AND PLASMA ARE IMMUNOLOGICALLY RELATED
    ERICKSON, LA
    HEKMAN, CM
    LOSKUTOFF, DJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (24) : 8710 - 8714
  • [10] DEVELOPMENT OF VENOUS OCCLUSIONS IN MICE TRANSGENIC FOR THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 GENE
    ERICKSON, LA
    FICI, GJ
    LUND, JE
    BOYLE, TP
    POLITES, HG
    MAROTTI, KR
    [J]. NATURE, 1990, 346 (6279) : 74 - 76
123